Revance Therapeutics Inc. (RVNC) announced after the close Monday that its Phase 3 trial of DaxibotulinumtoxinA Topical Gel did not achieve its co-primary and other endpoints. The company does not plan to continue development of the product for crow's feet.
from RTT - Before the Bell http://ift.tt/1UyYspI
via IFTTT
No comments:
Post a Comment